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Abstract
Imprinted genes with a parent-of-origin specific expression are involved in various aspects of growth that are
rooted in the prenatal period. Therefore it is predictable that many of the so far known congenital imprinting
disorders (IDs) are clinically characterised by growth disturbances. A noteable imprinting disorder is Silver-Russell
syndrome (SRS), a congenital disease characterised by intrauterine and postnatal growth retardation, relative
macrocephaly, a typical triangular face, asymmetry and further less characteristic features. However, the clinical
spectrum is broad and the clinical diagnosis often subjective. Genetic and epigenetic disturbances can meanwhile
be detected in approximately 50% of patients with typical SRS features. Nearly one tenth of patients carry a mater-
nal uniparental disomy of chromosome 7 (UPD(7)mat), more than 38% show a hypomethylation in the imprinting
control region 1 in 11p15. More than 1% of patients show (sub)microscopic chromosomal aberrations. Interestingly,
in ~7% of 11p15 hypomethylation carriers, demethylation of other imprinted loci can be detected. Clinically, these
patients do not differ from those with isolated 11p15 hypomethylation whereas the UPD(7)mat patients generally
show a milder phenotype. However, an unambiguous (epi)genotype-phenotype correlation can not be delineated.
We therefore suggest a diagnostic algorithm focused on the 11p15 hypomethylation, UPD(7)mat and cryptic chro-
mosomal imbalances for patients with typical SRS phenotype, but also with milder clinical signs only reminiscent
for the disease.
Review
Over the past 20 years it has become increasingly clear
that genomic imprinting is of great relevance for human
diseases. Imprinted genes with a parent-of-origin speci-
fic expression are involved in various aspects of growth
and behaviour that are rooted in the prenatal period
and indeed, many of the so far known congenital
imprinting disorders (IDs) are clinically characterised by
growth disturbances. While Angelman, Prader-Willi and
Beckwith-Wiedemann syndromes (BWS) are well estab-
lished IDs, imprinting defects in patients with Silver-
Russell syndrome (SRS) are relatively new findings.
The main features of SRS [RSS; OMIM 180860] are
severe intrauterine and postnatal growth retardation,
relative macrocephaly and a characteristic small, trian-
gular face. The disease is associated with additional dys-
morphic features including fifth finger clinodactyly and
hemihypoplasia (table 1). Although a clinical scoring
system to assist the diagnosis has recently been
suggested [1], the accuracy of diagnosis is influenced by
the experience of the clinical investigator. Furthermore,
the clinical picture of SRS in adulthood is less clear
than in early childhood.
The frequency of SRS is currently unknown, but it is
probably underdiagnosed due to the broad range of fea-
tures [1].
The influence of genetic factors in the aetiology of
SRS is documented by classical genetic findings such as
familial cases of SRS and cytogenetic aberrations. Most
cases of SRS are sporadic, but familial cases have been
reported (for review: [2]). Duncan et al. [2] suggested
that most familial cases were transmitted in an auto-
somal dominant manner with marked intrafamilial varia-
bility. An autosomal recessive inheritance has been
supposed in eight families but in six of them the clinical
documentation is questionable (for review: [3]). How-
ever, in only two families a recurrence of (epi)mutations
in 11p15 have been described [4].
In the following, an overview on the currently known
(epi)genetic disturbances in SRS will be given. We want to
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emphasize that the order of mutations does not reflect the
importance but their chronological identification.
Chromosomal aberrations and SRS
Several SRS patients have structural aberrations affecting
numerous chromosomes, but only chromosomes 7, 11,
and 17 were consistently involved in individuals fulfilling
strict diagnostic criteria of SRS. Based on balanced translo-
cations in two patients involving 17q24-q25 [5,6], a central
role of this chromosomal region in SRS aetiology had been
discussed for a long time. However, characterisation of the
17q breakpoints in both patients showed that they were
not identical [7]. The reported heterozygous deletions in
the growth hormone (GH) gene cluster in 17q [8] are now
regarded as apathogenic polymorphisms [9].
However, conventional cytogenetic analysis was ham-
pered in the past by the low microscopic resolution.
Thus the development of array-based techniques for
molecular karyotyping now allows the identification of
cryptic imbalances which formerly escaped microscopic
analysis. Meanwhile two studies reported on SRS
patients carrying small deletions/duplications < 3 Mb
[10,11]. In respect to genetic counselling, conventional
karyotyping should be considered in the patients’ par-
ents to detect balanced rearrangements.
Chromosome 7 and SRS
Cytogenetic aberrations of chromosome 7 including dupli-
cations of 7p11.2p13 and small marker chromosomes have
been identified in several SRS individuals (for review:
[12,13]). The first evidence for an involvement of this
chromosome in the aetiology of the disease was based on
the identification of maternal uniparental disomy of chro-
mosome 7 (UPD(7)mat) in ~10% of SRS individuals [14]
(table 1). Microsatellite typing patterns in nearly all these
UPD(7)mat carriers were consistent with the mechanism
of trisomic rescue. Due to the trisomic origin of UPD(7)
mat it might be assumed that trisomy 7 mosaicism is
involved in the aetiology of SRS. This hypothesis was cor-
roborated by the observation of a significant increase of
the frequency of completely skewed X inactivation in SRS
as a marker for undetected trisomy 7 in the patients and/
or their placentas [15]. Nevertheless, two studies detected
neither trisomy 7 cells in leukocytes nor in fibroblasts of
SRS patients [16,17], probably due to the lethality of gen-
eral trisomy 7 mosaicism and the limited number of tis-
sues analysed.
In cases of UPD, reduction to homozygosity of a
recessive allele is a further cause for aberrant pheno-
types, and indeed UPD was first described in a growth
retarded patient with cystic fibrosis who was homozy-
gous for a cystic fibrosis transmembrane regulator
gene mutation caused by a UPD(7)mat. Thus, reces-
sive mutations might be regarded as causative for
theSRS phenotype in UPD(7)mat patients, but there
is not a common isodisomic segment. This
finding excludes a “simple” recessive gene responsible
for SRS [18].
Table 1 Clinical features in SRS and their frequencies in the different molecular subgroups.(*combined from different
studies by [59])
clinical features total RSS n = 143 [58] UPD(7)mat [59] ICR1 hypomethylation carriers [59] idiopathic RSS [59]
growth parameters n = 129
birth weight (SD) 94% (< 3 Perc.) -2.79 (n = 37) -3.55 SD (n = 58) -3.1
birth length (SD) - 3.1 (n = 32) -4.38 SD (n = 57) -4.1
birth OFC (SD) - 1.26 (n = 28) -1.35 SD (n = 54) -1.5
postnatal growth retardation (SD) 99% -3.37 (n = 38) -3.41 (n = 49) -3.6
clinical features n = 388
relative macrocephaly 64% 92% 91% (n = 59) 68.4%
muscular hypotonia 45% 69.2% (n = 13) - 45%
asymmetry 51% 60% (n = 30) 77% (n = 57) 53.1%
clinodactyly V 68% 82% (n = 34) 78% (n = 40) 69.9%
squeaky voice 22%
developmental delay 37% 43% (n = 39) 20.5% (n = 31) 32.2%
craniofacial features
triangular face
79% 97% (n = 34) 76% (n = 59) 78.4%
prominent forehead 68% 88% (n = 34) 72.4%
downturned corners of the mouth 46% 50% (n = 22) 55% (n = 9) 57.3%
micrognathia 73% (n = 15) 55% (n = 9) 44%
ear anomalies 53% 78.6% (n = 14) 40.3%
teeth anomalies 28% 64% (n = 14) 0% (n = 7) 28%
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In conclusion, the most probable explanation for the
SRS phenotype in UPD(7)mat carriers is the disturbed
expression of imprinted genes on chromosome 7. UPD
(7)mat is generally associated with growth retardation
and SRS-like features whereas UPD(7)pat is not (for
review: [19]). It has therefore been hypothesized that (i)
a diminished expression of paternally expressed gene(s)
or (ii) an overexpression of maternally expressed factor
(s) on chromosome 7 causes SRS.
So far, research on chromosome 7 encoded factors has
focused on two chromosomal segments in 7p and 7q,
respectively. For the candidate region in 7p11.2-p13 SRS
patients with duplications have been reported (for
review: [12,20]). The region harbours an imprinted gene
(growth factor receptor bound protein 10/GRB10) and
several factors involved in human growth and develop-
ment (IGFBP1; IGFBP3; PHKG1; EGFR; GHRHR).
Pathogenic mutations in these genes have been excluded
in SRS [for review: [21]]. In particular, GRB10 plays an
essential role in growth and is therefore still a good can-
didate for SRS. This assumption is supported by a
recently published family carrying a maternally inherited
dup(7)(p11.2p12) not including GRB10 and without SRS
features [13]. Nevertheless, neither point mutations in
the coding region nor aberrant methylation of GRB10
have been detected in SRS patients despite extensive
screening studies (for review: [22-24]).
On the other hand, there is evidence that the chromo-
somal region 7q31 is also involved in SRS aetiology:
meanwhile four growth retarded patients with segmental
UPD(7q) have been identified [25-27]. In 7q31, three
imprinted genes (MEST/PEG1; CPA4; COPG2) and two
imprinted non-coding RNAs (MESTIT, CIT1/COP-
G2IT1) are localised but screening studies did not detect
any pathogenic variants [for review: [21]]. Furthermore,
isolated imprinting defects as reported for other
imprinting disorders have not yet been detected at the
MEST/PEG1 locus in SRS patients [28].
Because intrauterine growth retardation has also been
reported for UPDs of other chromosomes and is often
associated with confined placental mosaicism in human
pregnancies, several studies investigated the origin of
other chromosomes by microsatellite typing in SRS
patients. However, further UPDs have not been observed
[29-31].
Chromosome 11p15 and SRS
Currently, the largest molecular genetic subgroup of SRS
are individuals with epimutations and mutations in the
chromosomal region 11p15. First evidence for an invol-
vement of this region in the aetiology of the disease was
the identification of maternal 11p15 duplications in
growth retarded patients. Four out of these six cases
showed SRS features in addition to intrauterine and
postnatal growth retardation (for review: [32]). Interest-
ingly, the opposite disturbance - duplication of paternal
11p15 - is associated with BWS. Numerous genetic and
epigenetic alterations can be detected in BWS patients
(for review: [33]) but in more than 50% aberrant methy-
lation patterns in 11p15 are involved. The search for
epimutations in 11p15 in SRS patients was therefore
consequent and indeed, hypomethylation at the telo-
meric ICR1 in 11p15 regulating H19 and IGF2 expres-
sion could be identified in 38-63% of cases [34-37]
(table 2).
The 11p15 imprinting cluster contains a number of
imprinted genes the expression of which is regulated by
two different imprinting control regions (ICR1 and
ICR2), also called H19 DMR (differentially methylated
region) and KvDMR1 (fig. 1) and which are crucial for
the control of fetal growth.
The telomeric ICR1 confers a differential chromatin
architecture to the two parental alleles leading to reci-
procal expression of H19 and IGF2. The two genes are
coexpressed in endoderm- and mesoderm-derived tis-
sues during embryonic development and compete for
the same enhancers. The paternally expressed IGF2 is
involved in fetal development and growth [38,39].
Although H19 was one of the first noncoding transcripts
identified, its function is still unknown. Knockout of
H19 removing the whole RNA coding sequence but
leaving the promoter and surrounding transcription unit
intact had no effect on the imprinted expression of
IGF2 [40]. These results indicate that the RNA itself
might be non-functional, however the fact that H19 is a
relatively highly conserved gene among mammals (77%
identity between human and mouse) suggests a pro-
found functional relevance. A recent study suggests that
H19 functions as a primary micro RNA precursor
involved in the posttranscriptional downregulation of
specific mRNAs during vertebrate development [41].
The ICR1 contains seven CTCF target sites (CTCF1-
CTCF7) in the differentially methylated region 2 kb
upstream of H19 and shows allele specific methylation.
The zinc-finger binding factor CTCF binds to the
maternal unmethylated ICR1 copy and thereby forms a
chromatin boundary. This CTCF binding mechanism
blocks IGF2 expression and promotes H19 transcription
of the maternal 11p15 copy.
Table 2 Frequencies of the different types of (epi)
mutations in SRS
Type of (Epi)mutation Frequency in SRS
11p15: ICR1 hypomethylation ~40%
UPD(7)mat ~10%
11p15 duplications of maternal material 1-2%
further chromosomal aberrations ~1%
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The centromeric ICR2 regulates the (reciprocal)
expression of CDKN1C, KCNQ1 (potassium channel
KQT-family member 1) and further genes and is methy-
lated only on the maternal allele. Mutations in the
paternally suppressed CDKN1C gene account for up to
40% of familial BWS cases and 5-10% of sporadic
patients (table 1). The gene encodes a cyclin dependent
kinase inhibitor (p57KIP2) and is part of the p21CIP2Cdk
inhibitor family. Functional analysis of CDKN1C germ-
line mutations detected in two BWS patients showed
the loss of cell-cycle inhibition [42]. The gene of another
non-coding RNA in 11p15, KCNQ1OT1 (LIT1), is loca-
lised in intron 9 of the KCNQ1 gene. KCNQ1OT1 is
expressed by the paternal allele and probably represses
realisation of the CDKN1C gene. Loss of methylation
(LOM) of the maternal ICR2 allele correlates with
expression of KCNQ1OT1. In BWS, one central
physiological change caused by ICR2 (epi)mutations
(hypomethylation at ICR2) as well as CDKN1C point
mutations is the reduced expression of CDKN1C.
The 11p15 epimutation in SRS is typically a hypo-
methylation of the telomeric ICR1 (table 1). In contrast,
the most frequent alteration in BWS is hypomethylation
at the centromeric ICR2 accounting for ~50% of
patients, whereas ICR1 hypermethylation is diagnosed in
only 2-7% of BWS patients. Clinically, the majority of
ICR1 hypomethylation carriers fulfil the clinical criteria
of SRS [34] but the epimutation has also been diagnosed
in patients with only growth retardation and asymmetry
[36,43]. However, this disturbance has not yet been
detected in individuals with isolated pre- and postnatal
growth restriction [44].
The recent identification of a SRS patient with a
duplication restricted to the ICR2 [45] suggests that
CDKN1C IGF2 H19KCNQ1
KCNQ1OT1
paternal
maternal
normal
CH3
CH3
ICR1 epimutation
SRS
H19CDKN1C IGF2KCNQ1
KCNQ1OT1
11p15 duplications
UPD(11p15)mat
CDKN1C IGF2KCNQ1
KCNQ1OT1
H19
Figure 1 Epigenetic regulation of the two imprinting centre regions (ICR) in 11p15 and illustration of the types of (epi)mutations
detectable in SRS.
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both ICRs on 11p15 are involved in the aetiology of the
disease, like in BWS. This finding and further data
obtained from BWS patients and from studies in mice
suggest that ICR1 and ICR2 interact [46].
Postfertilisation origin of 11p15 hypomethylation
and aberrant methylation at multiple loci in SRS
The mosaic distribution of the 11p15 epimutation in
nearly all SRS patients can be attributed to a post-
fertilisation error. Clinically, this mocaicism is reflected
by hemihypoplasia, which is present in the majority of
these patients.
The data from twin studies are consistent with this
mosaic distribution of epimutations. In SRS, four discor-
dant but only one concordant monozygotic pair have
been observed (for review: [47]). These ambiguous find-
ings are consistent with the data of Gicquel et al. [35].
They reported discordant monozygotic twins carrying
the ICR1 epimutation in blood, but the affected twin
had LOM in skin fibroblasts. There have been similar
observations for the ICR2 locus in discordant BWS
twins with the same epigenetic defect in lymphocytes
but different methylation patterns in fibroblasts or buc-
cal mucosa [48,49]. In conclusion, the post-fertilisation
origin of the ICR1 or ICR2 epimutations explains the
high rate of discordance between twins with SRS or
BWS.
Further evidence for postzygotic defects in the estab-
lishment of imprinting marks is based on observations
in patients with transient neonatal diabetes mellitus
(TNDM), SRS and BWS who have LOM at further
maternally (and paternally) imprinted loci, in addition to
methylation defects typical for each disease [50,51]. In
cases of TNDM, the patients with additional LOMs had
a phenotype that is slightly different from those with
TNDM and LOM at 6q24 only, probably caused by the
altered methylation at the other imprinted loci. Based
on these findings, Mackay and coworkers [52] proposed
the existence of a maternal hypomethylation syndrome.
Recently, also BWS and SRS patients with multilocus
hypomethylation in blood lymphocytes have been
reported [49,51,53]. In these patients both paternally
and maternally imprinted loci were affected in leuko-
cytes. In monozygotic (MZ) twins discordant for BWS
Bliek and coworkers [49] observed similar imprinting
anomalies of one or more loci in leukocytes of both
twins but in buccal swab DNA the epimutations were
detectable only in the affected twin. In all studies, a phe-
notypic difference between BWS or SRS patients with
multiple hypomethylated loci and patients carrying iso-
lated 11p15 epimutations was not obvious.
Summarizing the data from these different conditions,
mosaicism of aberrant methylation suggests that the epi-
genetic error occurs after fertilisation and affects the
maintaining of the methylation signals at imprinted loci.
Methylation patterns are largely erased in primordial
germ cells and are re-established in sex-specific patterns
in mature male and female germ cells. The key regula-
tors in these processes are DNA methyltransferases and
methyl-binding domain proteins, but these mechanisms
remain largely to be elucidated. Insights in the complex-
ity of methylation pattern dynamics in the early embryo
and the mechanisms that establish and maintain geno-
mic methylation patterns have been provided by Howell
et al. [54]: In DNA methyltransferase-1 (Dnmt1) defi-
cient mice, genomic imprints were established normally
in oocytes, but there was an unexpected postzygotic loss
of methylation. Possibly Dnmt1 is required to maintain
methylation patterns at imprinted loci and only during a
single S phase in the early embryo. The establishment of
regular imprints could be demonstrated for the first
time in the offspring of Dnmt3L-/- mice [55]: in absence
of the DNA methyltransferase 3L (Dnmt3L) other factors
mark individual differentially methylated regions
(DMRs) alone but for an appropriate imprinting pattern
at all loci a combination of all involved factors is
necessary.
Diagnostic algorithm in patients with SRS and
SRS-like features
With the identification of the ICR1 hypomethylation in
11p15 and the UPD(7)mat the molecular confirmation
of the clinical diagnosis of SRS is now possible in ~50%
of patients (fig. 2).
All currently known patients with UPD(7)mat are the
result of a chromosomal nondisjunction event, in these
cases the recurrence risk is not increased in the families.
Meanwhile several patients with segmental UPD of the
long arm of chromosome 7 have been described, thus it
is meaningful to test patients for UPD(7)mat for both
known imprinted loci on the short and the long arm of
chromosome 7. We suggest to use methylation-specific
PCR approaches for both 7p and 7q loci because they
allow the detection of UPD(7)mat for diagnostic pur-
poses and the detection of so far unknown isolated
imprinting defects on chromosome 7. If a positive result
is obtained microsatellite typing is indicated to confirm
UPD(7)mat and to exclude the aforementioned isolated
imprinting defects and deletions.
In case of prenatal testing for UPD, methylation-speci-
fic tests might be hampered by the uncertainity whether
methylation is completed, thus microsatellite typing is
the tool of choices.
A large group of SRS patients shows an ICR1 hypo-
methylation in 11p15. Several testing procedures have
been reported for methylation analysis of the 11p15 loci,
the advantage of the methylation-specific multiplex liga-
tion probe-dependent analysis (MS-MLPA) approach is
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that copy number variation and aberrant methylation at
different loci in 11p15 can be detected in one tube.
Thus, methylation defects at both ICRs in 11p15 as well
as duplications and UPDs of this region will be identi-
fied. However, MS-MLPA as well as the other reported
tests have limitations such as sequence variants which
affect the probe hybridisation or incomplete bisulphite
conversion. Furthermore, we have to bear in mind that
routine diagnostics is based on lymphocytes and that
nearly all SRS patients with ICR1 hypomethylation are
mosaics. Thus we assume that a subgroup of patients
escapes molecular diagnosis because their mosaicism
affects tissues other than blood cells. In case of a strong
clinical suspicion of SRS but exclusion of the major
(epi)genetic disturbances we therefore suggest to analyse
a second cell system e.g. buccal epithelium. Whereas the
MS-MLPA patterns for aberrant methylation are unam-
biguous and generally do not need confirmation by a
second test, duplications/deletions and UPDs can only
be verified by microsatellite typing with 11p15 markers
or qPCR. It is currently difficult to estimate whether
methylation-specific tests for 11p15 imprinting regions
are an adequate tool for prenatal testing due to the
uncertainty of the timing of methylation at specific loci
in the embryo.
Recently, multiple hypomethylations at other loci than
the ICR1 have been demonstrated in up to 7% of
patients [53]. Currently, there are no obvious clinical
differences between patients with isolated ICR1 hypo-
methylation and those with multiple imprinting defects.
For research purposes, patients with ICR1 demethylation
might thus be tested for further imprinted loci.
After exclusion of 11p15 epimutation and UPD(7)mat,
molecular karyotyping can help to identify submicro-
scopic imbalances. Indeed, the frequency of chromoso-
mal imbalances in SRS is unknown but based on two
studies [10,11] on this subject we estimate that this
aberration accounts for ~1% of SRS patients.
By summarising the molecular genetic data from rou-
tine diagnostic cases referred as SRS we recently showed
that 11p15 epimutation and UPD(7)mat carriers do not
always exhibit the unambiguous SRS phenotype [1,34].
Indeed, genetic testing for both aberrations should also
be considered in case of “SRS-like” phenotypes, e.g. mild
intrauterine and postnatal growth retardation (> -2SD)
associated with a prominent forehead and triangular
Testing for 11p15 ICRs
Testing for UPD(7)mat
MS-Assays for further 
imprinted loci
UPD(7)mat
~10%
Molecular Karyotyping
No Result: 
~48%
ICR1 
hypomethylation
~40%
Genomic DNA sample
Aberrant methylation in 11p15 Normal methylation in 11p15
UPD(11p15)mat
Single cases
11p15 
duplications
1-2%
Normal result
Confirmation 
by MSA
Aberrant methylation 
at additional loci: ~7%
(Sub)microscopic 
Duplications/Deletions: 
~1%a
Confirmation 
by MSA
Confirmation by FISH, MLPA etc.
Figure 2 Diagnostic algorithm in children diagnosed as SRS. The algorithm should comprise MS-MLPA for the 11p15 loci and UPD(7)mat
testing for loci on both arms of the chromosome. (a the ratio is roughly estimated due to the limited numbers of systematic studies aiming on
submicroscopic imbalances in SRS; MSA: microsatellite analysis; MS assays: methylation-specific assays)
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face or asymmetry as the only clinical signs. In particu-
lar, the lack of IUGR in patients with a “SRS-like” phe-
notype should not automatically result in exclusion
from molecular testing.
Finally, the molecular proof of SRS is of particular
importance considering the subjectiveness of the clinical
diagnosis of SRS. With respect to genetic counselling,
the identification of ICR1 hypomethylation or maternal
UPD7 allows delineation of a low recurrence risk due to
their de-novo occurrence. First clinical characterisations
suggest that the phenotype of maternal UPD7 carriers is
generally milder whereas 11p15 epimutation carriers
usually present the typical picture of SRS [56,57].
Further phenotype analyses will help to find out
whether the molecular subgroups of SRS respond differ-
ently to growth hormone treatment as suggested by
Binder et al. [58].
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